# K140280: Forticore

- Pathway: 510(k) (Traditional)
- Applicant: Nanovis, LLC
- Decided: Sep 5, 2014 after 213 days
- Product code: ODP (Intervertebral Fusion Device With Bone Graft, Cervical)
- Device class: 2
- Regulation: 21 CFR 888.3080
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 14 generations back to K003155 (2001). 86 ancestors in all.
9 later devices descend from it; 6 cite it directly.
1 of 96 devices in its family (counting itself) has a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K110442: Nanovis Intervertebral Body Fusion System, Nanovis, LLC (2011) Summary page 5.
- K081614: Zeus Small Cervical Cage and Large, Extra Large, Curved and Straight Lumbar Cages, Interbody Innovations, Llp (2008) Summary page 5.

## Most influential descendants
- K161485: Nanovis Intervertebral Body Fusion System and Forticore (R) (2016), 5 descendants of its own
- K160874: Nanovis Intervertebral Body Fusion System and FortiCore® (2016), 4 descendants of its own
- K171312: FortiCore® (2018), 3 descendants of its own
- K191822: Nano FortiCore, FortiCore (2019), 2 descendants of its own
- K241605: Adaptix™ PEEK Interbody System with Nanotechnology; Capstone Control™ PEEK Spinal System with Nanotechnology (2024), 0 descendants of its own

## Indications for use
When used as a cervical intervertebral body fusion device, FortiCore™ is intended for spinal fusion procedures in skeletally mature patients with degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies) at one spinal level from C2-T1. These patients should have had at least six weeks of non-operative treatment. FortiCore™ devices are to be used with autogenous bone graft and in combination with supplemental fixation indicated for cervical fusion procedures. When used as a lumbar intervertebral body fusion device, FortiCore™ is intended for spinal fusion procedures in skeletally mature patients with degenerative disc disease (defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies) at one or two contiguous spinal levels from L2-S1. These patients should have had six months of nonoperative treatment. These patients may have had a previous non-fusion spinal surgery and/or may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved spinal level(s). FortiCore™ devices are to be used with autogenous bone graft and in combination with supplemental fixation indicated for lumbar spinal fusion procedures.

Source page: https://510kreport.com/device/K140280
Methodology: https://510kreport.com/methodology